Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

Autor: Koenig, Lars M., Boehmer, Daniel F.R., Metzger, Philipp, Schnurr, Max, Endres, Stefan, Rothenfusser, Simon
Zdroj: The Journal of Experimental Medicine; September 2020, Vol. 217 Issue: 9 pe20201342-e20201342, 1p
Abstrakt: An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.
Databáze: Supplemental Index